Biogen (BIIB) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Biogen (BIIB) do?
Biogen Inc (BIIB) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures and sells specialized therapies for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Specializes in developing and manufacturing prescription therapies targeting complex neurological and neurodegenerative. It is worth $36.53B on the market and sold $9.90B over the last year.
- Market cap
- $36.53B
- P/E ratio
- 105.8×
- Annual sales
- $9.90B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Brief updated
- Nov 13, 2026
Brands and businesses behind BIIB
- Spinraza: Prescription treatment for spinal muscular atrophy sold directly to hospitals and specialty medical providers.
- Skyclarys: Once-daily capsule for Friedreich's ataxia generating revenue through specialized pharmacy distribution channels.
- Tysabri: Infusion therapy for severe multiple sclerosis sold to healthcare clinics and specialized infusion centers.
- Tecfidera: Oral capsule for relapsing multiple sclerosis generating revenue through commercial prescription sales.
- Vumerity: Prescription oral pill for relapsing multiple sclerosis that earns revenue through retail and specialty pharmacies.
- Leqembi: Infusion drug for early Alzheimer's disease that generates revenue through a global profit-sharing partnership.
BIIB’s flags, in plain English
Each flag is a number from Biogen’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.
Wide Gross Margin
Gross margin of 64% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Stupid Cash
Can pay this year's bills 2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 41% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Priced for Perfection
Priced at 105.8 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about BIIB
How big is Biogen?
Biogen’s market cap is $36.53B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $9.90B: what customers paid the company over the last year, before any costs.
What is BIIB’s P/E ratio?
BIIB’s P/E ratio is 105.8×. Investors pay about 105.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with BIIB?
Patent expirations and generic alternatives have eroded sales from older multiple sclerosis therapies such as Tecfidera. That is one risk on Biogen’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Biogen’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BIIB’s filings on SEC.gov. The Margin Monkey is research, not advice.
